Maastricht. Monitorización Acumulativa de las Necesidades y modelo holandés de Tratamiento Asertivo ComunitarioImplicaciones para el programa GAZTE.

  1. Irurzun Palacios, Juan Carlos
  2. Martín, Leire
  3. Bastida, Maite
Zeitschrift:
Norte de Salud Mental

ISSN: 1578-4940

Datum der Publikation: 2011

Ausgabe: 9

Nummer: 41

Seiten: 31-37

Art: Artikel

DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Andere Publikationen in: Norte de Salud Mental

Zusammenfassung

Here we present the ideas developed in Maastricht (Netherland) in the field of care of people with Severe Mental Disorder. The �cumulative needs for care monitor� for assessment and the �function or flexible assertive community treatment� as a way to organize assistance are the main points. We also highlight the importance of monitoring the physical health and propose some considerations on the application of these ideas to our setting.

Bibliographische Referenzen

  • Bak M., van Os J., Delespaul Ph., et al. An ob- servational, ‘real life’ trial of the introduction of assertive community treatment in a geographically defined area using clinical rather than service use outcome criteria. Soc Psychiatry Psychiatr Epidemiol 2007; 42:125- 130.
  • Drukker M., van Os J., Bak M., à Campo J., Delepaul Ph. Systematic monitoring of needs for care and global outcomes in patients with severe mental illness. BMC Psychiatry 2010; 10:36.
  • Drukker M., Bak M., à Campo J., Driessen G., van Os J., Delespaul Ph. The cumulative needs for care monitor: a unique monitoring system in the south of the Netherlands. Soc Psychiat Epidemiol 2010; 45: 475-485.
  • Drukker M., van Os J., Dietvorst M., Sytema S., Driessen G., Delespaul Ph. Does monitoring need for care in patients diagnosed with severe mental illness impact on Psychiatric Service Use? Comparison of monitored patients with matched controls. BMC Psychiatry 2011; 11:45.
  • Irurzun JC., Bastida M., Campos C., Neira N., Oyarzabal E., Palomo E., Zarraga K. Programa de Atención a Personas Jóvenes con Psicosis GAZTE. Norte de salud mental, 2010, vol. VIII, nº 37: 103-112.
  • McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Da- vis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005; 80:19-32.
  • Remmers van Veldhuizen J. FACT: a Dutch version of ACT. Community Mental Health Journal 2007; 43, 4: 421-433.
  • Suvisaari J, Perala J, Saarni SI, Harkanen T, Pirkola S, Koskinen S, Lonngvist J, Reunanen A. Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey.
  • Tarricone I, Ferrari Gozzi B, Serreto A, Grieco D, Berardi D.Weight gain in antipsychotic-naive patients: a review and meta-analysis. [Review] [94 refs].
  • Van Os J., Delespaul Ph. Psychosis research at Maastricht University, The Netherlands. British Journal of Psychiatry 2003; 183: 559-560.
Fuente de los datos: Dialnet